Insulet Corporation (NASDAQ:PODD) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. lowered its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 41.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,232 shares of the medical instruments supplier's stock after selling 881 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Insulet were worth $324,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in Insulet during the 4th quarter valued at $36,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Insulet during the 4th quarter worth $42,000. SRS Capital Advisors Inc. boosted its position in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares in the last quarter. Assetmark Inc. boosted its position in Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares in the last quarter. Finally, Coppell Advisory Solutions LLC grew its stake in Insulet by 135.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after purchasing an additional 162 shares during the last quarter.

Insiders Place Their Bets

In other news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president owned 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.39% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PODD shares. Truist Financial started coverage on shares of Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price target on the stock. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a research report on Monday, April 28th. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Finally, The Goldman Sachs Group initiated coverage on Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 target price on the stock. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $321.00.

Insulet Stock Performance

NASDAQ PODD traded up $1.10 during trading hours on Monday, reaching $314.18. The stock had a trading volume of 679,918 shares, compared to its average volume of 713,755. Insulet Corporation has a 52-week low of $129.55 and a 52-week high of $329.33. The stock has a fifty day moving average of $297.69 and a 200 day moving average of $277.69. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. The stock has a market cap of $22.11 billion, a P/E ratio of 56.51, a price-to-earnings-growth ratio of 2.79 and a beta of 1.37.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The business's quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.73 EPS. Sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.